IMRICOR 1H 2025 Results

HIGHLIGHTS:

Regulatory

- Successful submission of 2nd Premarket Approval (PMA) Module to US FDA
- CE Mark approval under MDR received for:
    - 2nd generation Vision-MR Ablation Catheter
    - 2nd generation Vision-MR Advantage EP Recorder/Stimulator
    - NorthStar – the world's first and only MRI native 3D mapping & guidance system
- First-in-man ventricular ablation guided by real-time iCMR was performed at Amsterdam University Medical Centre (AUMC), commencing VISABL-VT clinical trial
- Additional VISABL-VT clinical trial sites preparing to enrol, focusing on strong Key Opinion Leaders (KOL's) at high volume sites
- Multiple US hospitals with existing MRI scanners in the cardiology department are progressing towards joining VISABL-AFL clinical trial

Commercial

- Deeply experienced sales team in place in Europe with training now complete
- Material impact on customer pipeline which increased from **7 to 26** over the half.
- Imricor B.V. established in The Netherlands where NorthStar development work will be accelerated to harvest more value from MRI data
- Two iCMR labs currently under construction in the Kingdom of Saudi Arabia will start the expansion into the Middle East

Financial

- Revenue of $196k temporarily impacted by VISABL-AFL clinical trial participation by customer sites.
- As trial completes, and pipeline begins to convert, revenue will begin to increase with a step change expected following US FDA approval.
- Balance sheet remains strong with US$50.3m cash at bank
- The Company will host a webinar today at 8:30am AEST / 5:30pm CDT
  Click here to register.

25 August 2025 – Minneapolis, MN United States (**26 August 2025** – Melbourne, Australia) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**), the global leader in real-time iCMR cardiac ablation products, today releases its 1H25 Financial Results for the period ended 30 June 2025 and provides an update on its operational performance.

Imricor's Chair and CEO, Steve Wedan, commented: "The electrophysiology market we're targeting has surged to over US$12 billion, and it's growing rapidly. To be a true disruptor requires more than incremental innovation. It demands a transformative leap. That's exactly what Imricor's focus has been, a revolutionary technology platform that redefines individualised medicine by integrating real-time MRI with our unique ecosystem of devices, capital equipment, and software. This is not just the next step in cardiac ablation; we believe it's the start of a new standard of care."

Webinar

The Company will host an investor webinar today at 8:30am AEST / 5:30pm CDT with Imricor's Chair and CEO, Steve Wedan, and CFO, Jonathon Gut.

Register at: https://us02web.zoom.us/webinar/register/WN_CoJnlNFLQOevPbDkDc0ezQ

Imricor background

Imricor is leading the new field of *real-time iCMR cardiac ablations* – that is, cardiac ablations guided by real-time magnetic resonance imaging (MRI), rather than by conventional x-ray fluoroscopy. iCMR (*interventional cardiac magnetic resonance*) is the term used to describe such interventional procedures performed in conjunction with MRI. The goal is to provide faster, safer, and more effective treatments of cardiac arrhythmias compared to conventional means.

Imricor is the only company in the world that provides MRI-compatible consumable devices, such as single-use ablation catheters, required to perform cardiac ablations in an iCMR lab.

Benefits of real-time iCMR cardiac ablations are derived from the superior imaging capabilities of MRI compared to x-ray, especially when it comes to imaging the heart and vascular structures which are largely invisible to x-rays. The goal of MRI guidance is to enable faster, more effective, and less expensive treatment of cardiac arrhythmias, all in a setting that is free of dangerous x-ray radiation exposure for patients, physicians, and other medical personnel.

Imricor's target market of cardiac ablations is estimated to be US$8 billion worldwide.

Executing the VISABL-VT and VISABL-AFL trials, as well as re-establishing the iCMR-guided atrial flutter ablation market in Europe, post-pandemic, and expanding into new geographies are key drivers of Imricor's growth.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union, the Kingdom of Saudi Arabia (KSA), and New Zealand with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in the U.S. and the other Middle East countries.

The Company has also obtained approval within the EU and certain Middle East countries for the sale of the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE HealthCare help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (ASX). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.